MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.44 -1.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.43

Máximo

1.52

Indicadores-chave

By Trading Economics

Rendimento

-428M

-426M

Vendas

-2.1M

37M

Margem de lucro

-1,146.812

Funcionários

575

EBITDA

-420M

-403M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+48.3% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

141M

480M

Abertura anterior

2.81

Fecho anterior

1.44

Sentimento de Notícias

By Acuity

50%

50%

148 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de jul. de 2025, 22:07 UTC

Grandes Movimentos do Mercado

Trade Desk Rises on S&P 500 Inclusion

14 de jul. de 2025, 17:06 UTC

Grandes Movimentos do Mercado

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 de jul. de 2025, 16:47 UTC

Aquisições, Fusões, Aquisições de Empresas

NatWest to Sell Stake in Permanent TSB

14 de jul. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

14 de jul. de 2025, 23:38 UTC

Conversa de Mercado

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 de jul. de 2025, 23:37 UTC

Conversa de Mercado

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 de jul. de 2025, 23:29 UTC

Conversa de Mercado

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 de jul. de 2025, 23:29 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 de jul. de 2025, 23:02 UTC

Ganhos

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 de jul. de 2025, 23:01 UTC

Ganhos

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 de jul. de 2025, 23:01 UTC

Ganhos

China Vanke Expects 1H Loss to Widen >000002.SZ

14 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

14 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de jul. de 2025, 20:07 UTC

Conversa de Mercado

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 de jul. de 2025, 20:05 UTC

Conversa de Mercado

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 de jul. de 2025, 19:11 UTC

Conversa de Mercado

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 de jul. de 2025, 19:09 UTC

Conversa de Mercado

Gold Breaks a 3-Day Win Streak -- Market Talk

14 de jul. de 2025, 18:59 UTC

Conversa de Mercado

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 de jul. de 2025, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 de jul. de 2025, 18:25 UTC

Conversa de Mercado

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 de jul. de 2025, 18:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de jul. de 2025, 16:59 UTC

Conversa de Mercado

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 de jul. de 2025, 16:53 UTC

Ações em Alta

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 de jul. de 2025, 16:27 UTC

Conversa de Mercado

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 de jul. de 2025, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

14 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

14 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

14 de jul. de 2025, 16:12 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

48.3% parte superior

Previsão para 12 meses

Média 2.18 USD  48.3%

Máximo 3 USD

Mínimo 1.25 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

4

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

148 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.